• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    eXoZymes Inc. - Common Stock (NQ:EXOZ)

    7.100 +0.370 (+5.50%)
    Streaming Delayed Price Updated: 1:43 PM EDT, Sep 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,121
    Open 7.220
    Bid (Size) 6.730 (100)
    Ask (Size) 7.240 (300)
    Prev. Close 6.730
    Today's Range 6.990 - 7.220
    52wk Range 4.350 - 18.40
    Shares Outstanding 8,387,250
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Investor Summit | MicroCap Opportunities to Watch - August 26
    From Investor Summit Group
    Via ACCESS Newswire
    News headline image
    eXoZymes Q2 Earnings Call Highlights ↗
    eXoZymes (NASDAQ:EXOZ) outlined progress toward commercializing its NCT program, including a reported tenfold increase in process productivity versus its March pilot campaign, while management said it... 
    Via MarketBeat
    Topics Earnings

    Performance

    YTD
    -35.4%
    -35.4%
    1 Month
    +54.3%
    +54.3%
    3 Month
    -26.6%
    -26.6%
    6 Month
    -12.2%
    -12.2%
    1 Year
    -26.7%
    -26.7%

    More News

    Read More
    News headline image
    eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today
    From eXoZymes
    Via ACCESS Newswire
    News headline image
    eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets
    From eXoZymes
    Via ACCESS Newswire
    News headline image
    eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026
    From eXoZymes
    Via ACCESS Newswire
    News headline image
    eXoZymes Provides Fourth Quarter and Full Year 2025 Update
    Via ACCESS Newswire
    News headline image
    Earnings Scheduled For November 13, 2025 ↗
    Via Benzinga
    News headline image
    eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing
    From eXoZymes
    Via ACCESS Newswire
    News headline image
    Q2 Virtual Investor Summit Presentations Now Available On Demand
    From Investor Summit Group
    Via ACCESS Newswire
    News headline image
    eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery
    From eXoZymes
    Via ACCESS Newswire
    News headline image
    eXoZymes Inc. Announces Closing of $6 Million Public Offering
    From eXoZymes
    Via ACCESS Newswire
    News headline image
    eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants
    Via ACCESS Newswire
    News headline image
    eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program
    Via ACCESS Newswire
    News headline image
    eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast
    Via ACCESS Newswire
    News headline image
    eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026
    Via ACCESS Newswire
    News headline image
    Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability
    Via ACCESS Newswire
    News headline image
    eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium
    Via ACCESS Newswire
    News headline image
    With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation
    Via ACCESS Newswire
    News headline image
    eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run
    Via ACCESS Newswire
    News headline image
    eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion
    Via ACCESS Newswire
    News headline image
    eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today
    Via ACCESS Newswire
    News headline image
    eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff
    Via ACCESS Newswire
    News headline image
    eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST
    Via ACCESS Newswire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference
    Via ACCESS Newswire

    Frequently Asked Questions

    Is eXoZymes Inc. - Common Stock publicly traded?
    Yes, eXoZymes Inc. - Common Stock is publicly traded.
    What exchange does eXoZymes Inc. - Common Stock trade on?
    eXoZymes Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for eXoZymes Inc. - Common Stock?
    The ticker symbol for eXoZymes Inc. - Common Stock is EXOZ on the Nasdaq Stock Market
    What is the current price of eXoZymes Inc. - Common Stock?
    The current price of eXoZymes Inc. - Common Stock is 7.100
    When was eXoZymes Inc. - Common Stock last traded?
    The last trade of eXoZymes Inc. - Common Stock was at 09/01/26 01:43 PM ET
    What is the market capitalization of eXoZymes Inc. - Common Stock?
    The market capitalization of eXoZymes Inc. - Common Stock is 59.55M
    How many shares of eXoZymes Inc. - Common Stock are outstanding?
    eXoZymes Inc. - Common Stock has 60M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.